Copyright
©The Author(s) 2019.
World J Gastroenterol. Oct 14, 2019; 25(38): 5883-5896
Published online Oct 14, 2019. doi: 10.3748/wjg.v25.i38.5883
Published online Oct 14, 2019. doi: 10.3748/wjg.v25.i38.5883
Figure 6 Differences between patients with or without preS deletion mutants.
A: Differences between patients with or without preS deletion mutants at fibrosis level; B: Differences between patients with or without preS deletion mutants at evolution of transaminase levels during follow-up. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.
- Citation: Gil-García AI, Madejón A, Francisco-Recuero I, López-López A, Villafranca E, Romero M, García A, Olveira A, Mena R, Larrubia JR, García-Samaniego J. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment. World J Gastroenterol 2019; 25(38): 5883-5896
- URL: https://www.wjgnet.com/1007-9327/full/v25/i38/5883.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i38.5883